BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 32034075)

  • 1.
    Sato N; Stringaris K; Davidson-Moncada JK; Reger R; Adler SS; Dunbar C; Choyke PL; Childs RW
    Clin Cancer Res; 2020 Jun; 26(11):2573-2581. PubMed ID: 32034075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. (89)Zr-Oxine Complex PET Cell Imaging in Monitoring Cell-based Therapies.
    Sato N; Wu H; Asiedu KO; Szajek LP; Griffiths GL; Choyke PL
    Radiology; 2015 May; 275(2):490-500. PubMed ID: 25706654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tracking of NK Cells by Positron Emission Tomography Using
    Sato N; Szajek LP; Choyke PL
    Methods Mol Biol; 2022; 2463():153-161. PubMed ID: 35344173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone Marrow Cell Trafficking Analyzed by
    Asiedu KO; Koyasu S; Szajek LP; Choyke PL; Sato N
    Clin Cancer Res; 2017 Jun; 23(11):2759-2768. PubMed ID: 27965305
    [No Abstract]   [Full Text] [Related]  

  • 5. Imaging of cell-based therapy using
    Kurebayashi Y; Choyke PL; Sato N
    Nanotheranostics; 2021; 5(1):27-35. PubMed ID: 33391973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET of Adoptively Transferred Chimeric Antigen Receptor T Cells with
    Weist MR; Starr R; Aguilar B; Chea J; Miles JK; Poku E; Gerdts E; Yang X; Priceman SJ; Forman SJ; Colcher D; Brown CE; Shively JE
    J Nucl Med; 2018 Oct; 59(10):1531-1537. PubMed ID: 29728514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with
    Leland P; Kumar D; Nimmagadda S; Bauer SR; Puri RK; Joshi BH
    J Transl Med; 2023 Jun; 21(1):367. PubMed ID: 37286997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A kit formulation for the preparation of [
    Man F; Khan AA; Carrascal-Miniño A; Blower PJ; T M de Rosales R
    Nucl Med Biol; 2020; 90-91():31-40. PubMed ID: 32979725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility study of
    Wang XY; Wang Y; Wu Q; Liu JJ; Liu Y; Pan DH; Qi W; Wang LZ; Yan JJ; Xu YP; Wang GJ; Miao LY; Yu L; Yang M
    Acta Pharmacol Sin; 2021 May; 42(5):824-831. PubMed ID: 32901086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation and (111)In-Oxine Labeling of Murine NK Cells for Assessment of Cell Trafficking in Orthotopic Lung Tumor Model.
    Malviya G; Nayak T; Gerdes C; Dierckx RA; Signore A; de Vries EF
    Mol Pharm; 2016 Apr; 13(4):1329-38. PubMed ID: 26962716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced Bone Marrow Homing of Natural Killer Cells Following mRNA Transfection With Gain-of-Function Variant CXCR4
    Levy E; Reger R; Segerberg F; Lambert M; Leijonhufvud C; Baumer Y; Carlsten M; Childs R
    Front Immunol; 2019; 10():1262. PubMed ID: 31231387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spatio-temporal biodistribution of
    Sta Maria NS; Khawli LA; Pachipulusu V; Lin SW; Zheng L; Cohrs D; Liu X; Hu P; Epstein AL; Jacobs RE
    Sci Rep; 2021 Jul; 11(1):15077. PubMed ID: 34302002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab.
    England CG; Ehlerding EB; Hernandez R; Rekoske BT; Graves SA; Sun H; Liu G; McNeel DG; Barnhart TE; Cai W
    J Nucl Med; 2017 Jan; 58(1):162-168. PubMed ID: 27493273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimisation of the Synthesis and Cell Labelling Conditions for [
    Friberger I; Jussing E; Han J; Goos JACM; Siikanen J; Kaipe H; Lambert M; Harris RA; Samén E; Carlsten M; Holmin S; Tran TA
    Mol Imaging Biol; 2021 Dec; 23(6):952-962. PubMed ID: 34231103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-Time Tracking of
    Uong TNT; Lee KH; Ahn SJ; Kim KW; Min JJ; Hyun H; Yoon MS
    Front Immunol; 2018; 9():825. PubMed ID: 29770131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vivo PET Imaging of
    Pham TT; Chenoweth A; Patel N; Banu A; Osborn G; Blower PJ; Karagiannis SN; Ma MT
    J Nucl Med; 2024 Jun; ():. PubMed ID: 38844362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biodistribution of 89Zr-oxine-labeled human bone marrow-derived mesenchymal stem cells by micro-PET/computed tomography imaging in Sprague-Dawley rats.
    Wang S; Wang Y; Xu B; Qin T; Lv Y; Yan H; Shao Y; Fang Y; Zheng S; Qiu Y
    Nucl Med Commun; 2022 Jul; 43(7):834-846. PubMed ID: 35438673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET.
    Rizvi SN; Visser OJ; Vosjan MJ; van Lingen A; Hoekstra OS; Zijlstra JM; Huijgens PC; van Dongen GA; Lubberink M
    Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):512-20. PubMed ID: 22218876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow cell homing to sites of acute tibial fracture:
    Asiedu KO; Ferdousi M; Ton PT; Adler SS; Choyke PL; Sato N
    EJNMMI Res; 2018 Dec; 8(1):109. PubMed ID: 30547233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between
    Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.